156 related articles for article (PubMed ID: 16569890)
1. Ritonavir increases plasma amprenavir (APV) exposure to a similar extent when coadministered with either fosamprenavir or APV.
Wire MB; Baker KL; Jones LS; Shelton MJ; Lou Y; Thomas GJ; Berrey MM
Antimicrob Agents Chemother; 2006 Apr; 50(4):1578-80. PubMed ID: 16569890
[TBL] [Abstract][Full Text] [Related]
2. Fosamprenavir plus ritonavir increases plasma ketoconazole and ritonavir exposure, while amprenavir exposure remains unchanged.
Wire MB; Ballow CH; Borland J; Shelton MJ; Lou Y; Yuen G; Lin J; Lewis EW
Antimicrob Agents Chemother; 2007 Aug; 51(8):2982-4. PubMed ID: 17517848
[TBL] [Abstract][Full Text] [Related]
3. Fosamprenavir/ritonavir plus tenofovir does not affect amprenavir pharmacokinetics: no effect of tenofovir.
Kurowski M; Walli RK; Breske A; Kruse G; Stocker H; Banik N; Richter H; Mazur D
AIDS; 2007 Jun; 21(10):1368-70. PubMed ID: 17545717
[TBL] [Abstract][Full Text] [Related]
4. Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers.
Luber AD; Condoluci DV; Slowinski PD; Andrews M; Olson K; Peloquin CA; Pappa KA; Pakes GE;
HIV Med; 2010 Mar; 11(3):193-9. PubMed ID: 19863619
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects.
Cao YJ; Smith PF; Wire MB; Lou Y; Lancaster CT; Causon RC; Bigelow GE; Martinez E; Fuchs EJ; Radebaugh C; McCabe S; Hendrix CW
Pharmacotherapy; 2008 Jul; 28(7):863-74. PubMed ID: 18576901
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of concurrent administration of fosamprenavir and atazanavir without ritonavir in human immunodeficiency virus-negative subjects.
McRae M; Clay PG; Anderson PL; Glaros AG
Pharmacotherapy; 2009 Aug; 29(8):937-42. PubMed ID: 19637947
[TBL] [Abstract][Full Text] [Related]
7. Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers.
Ruane PJ; Luber AD; Wire MB; Lou Y; Shelton MJ; Lancaster CT; Pappa KA;
Antimicrob Agents Chemother; 2007 Feb; 51(2):560-5. PubMed ID: 17088488
[TBL] [Abstract][Full Text] [Related]
8. Interaction between fosamprenavir, with and without ritonavir, and nevirapine in human immunodeficiency virus-infected subjects.
DeJesus E; Piliero PJ; Summers K; Wire MB; Stein DS; Masterman A; Lou Y; Min SS; Shelton MJ
Antimicrob Agents Chemother; 2006 Sep; 50(9):3157-9. PubMed ID: 16940117
[TBL] [Abstract][Full Text] [Related]
9. Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers.
Luber AD; Brower R; Kim D; Silverman R; Peloquin CA; Frank I
HIV Med; 2007 Oct; 8(7):457-64. PubMed ID: 17760738
[TBL] [Abstract][Full Text] [Related]
10. Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment.
Seminari E; De Bona A; Gentilini G; Galli L; Schira G; Gianotti N; Uberti-Foppa C; Soldarini A; Dorigatti F; Lazzarin A; Castagna A
J Antimicrob Chemother; 2007 Oct; 60(4):831-6. PubMed ID: 17684056
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic and safety evaluation of high-dose combinations of fosamprenavir and ritonavir.
Shelton MJ; Wire MB; Lou Y; Adamkiewicz B; Min SS
Antimicrob Agents Chemother; 2006 Mar; 50(3):928-34. PubMed ID: 16495253
[TBL] [Abstract][Full Text] [Related]
12. Fosamprenavir calcium plus ritonavir for HIV infection.
Torres HA; Arduino RC
Expert Rev Anti Infect Ther; 2007 Jun; 5(3):349-63. PubMed ID: 17547501
[TBL] [Abstract][Full Text] [Related]
13. Effect of antacids and ranitidine on the single-dose pharmacokinetics of fosamprenavir.
Ford SL; Wire MB; Lou Y; Baker KL; Stein DS
Antimicrob Agents Chemother; 2005 Jan; 49(1):467-9. PubMed ID: 15616339
[TBL] [Abstract][Full Text] [Related]
14. Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.
Pham PA; Hendrix CW; Barditch-Crovo P; Parsons T; Khan W; Parish M; Radebaugh C; Carson KA; Pakes GE; Qaqish R; Flexner C
Antivir Ther; 2007; 12(6):963-9. PubMed ID: 17926651
[TBL] [Abstract][Full Text] [Related]
15. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.
Gathe JC; Wood R; Sanne I; DeJesus E; Schürmann D; Gladysz A; Garris C; Givens N; Elston R; Yeo J
Clin Ther; 2006 May; 28(5):745-54. PubMed ID: 16861096
[TBL] [Abstract][Full Text] [Related]
16. Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.
Arvieux C; Tribut O
Drugs; 2005; 65(5):633-59. PubMed ID: 15748098
[TBL] [Abstract][Full Text] [Related]
17. Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin.
Busti AJ; Bain AM; Hall RG; Bedimo RG; Leff RD; Meek C; Mehvar R
J Cardiovasc Pharmacol; 2008 Jun; 51(6):605-10. PubMed ID: 18520949
[TBL] [Abstract][Full Text] [Related]
18. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
Molina JM; Ait-Khaled M; Rinaldi R; Penco G; Baril JG; Cauda R; Soriano V; Pialoux G; Wire MB; Lou Y; Givens N; Craig C; Nichols WG; Barbosa I; Yeo J;
J Antimicrob Chemother; 2009 Aug; 64(2):398-410. PubMed ID: 19515730
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetic modeling and simulation of amprenavir following fosamprenavir/ritonavir administration for dose optimization in HIV infected pediatric patients.
Barbour AM; Gibiansky L; Wire MB
J Clin Pharmacol; 2014 Feb; 54(2):206-14. PubMed ID: 25272370
[TBL] [Abstract][Full Text] [Related]
20. Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis.
Gatti F; Nasta P; Loregian A; Puoti M; Matti A; Pagni S; de Requena DG; Prestini K; Parisi SG; Bonora S; Palù G; Carosi G
J Antimicrob Chemother; 2009 Mar; 63(3):575-8. PubMed ID: 19151039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]